News

Receptor transplant makes blind mice see
Enlarge image

ResearchUK

Receptor transplant makes blind mice see

19.04.2012 - British researchers have shown for the first time that transplanting photoreceptors into the eyes of blind mice can restore their vision.

London – The findings reported in Nature suggests that transplanting light-sensitive nerve cells that line the back of the eye could form the basis of a new treatment to restore sight in people with degenerative eye diseases including age-related macular degeneration, retinitis pigmentosa and diabetes-related blindness.
The team, led by Professor Robin Ali with researchers at University College London, injected immature cells from young healthy mice directly into the retinas of adult mice that lacked functional rod-photoreceptors. After four to six weeks, the transplanted cells appeared to be functioning almost as well as normal rod-photoreceptor cells and had formed the connections needed to transmit visual information to the brain.
The researchers also tested the vision of the treated mice in a dimly lit maze. Those mice with newly transplanted rod cells were able to use a visual cue to quickly find a hidden platform in the maze whereas untreated mice were able to find the hidden platform only by chance after extensive exploration of the maze.
"We've shown for the first time that transplanted photoreceptor cells can integrate successfully with the existing retinal circuitry and truly improve vision. We're hopeful that we will soon be able to replicate this success with photoreceptors derived from embryonic stem cells and eventually to develop human trials.

http://www.european-biotechnology-news.com/news/news/2012-02/receptor-transplant-makes-blind-mice-see.html

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.30 CHF176.60%
  • MEDIGENE4.97 EUR9.23%
  • FORMYCON18.70 EUR7.47%

FLOP

  • VITA 345.30 EUR-5.36%
  • BIOFRONTERA1.98 EUR-4.35%
  • ADDEX3.06 CHF-3.16%

TOP

  • CYTOS1.30 CHF282.4%
  • WILEX3.23 EUR51.6%
  • FORMYCON18.70 EUR25.1%

FLOP

  • MOLOGEN5.13 EUR-16.0%
  • SANTHERA96.10 CHF-12.4%
  • MAGFORCE5.44 EUR-10.8%

TOP

  • SANTHERA96.10 CHF2339.1%
  • WILEX3.23 EUR429.5%
  • FORMYCON18.70 EUR142.9%

FLOP

  • MOLOGEN5.13 EUR-56.7%
  • PAION2.06 EUR-54.6%
  • CYTOS1.30 CHF-54.4%

No liability assumed, Date: 06.03.2015